Somatic Mosaicism in Twins Discordant for Childhood Cancer

Overseen By Jenny Poynter, PhD

Age: < 65

Sex: Any

Trial Phase: Academic

Sponsor: Children's Oncology Group

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

50 Participants Needed

Trial Summary

What is the purpose of this trial?

Somatic mosaicism in cancer associated genes is one potential explanation for discordance in childhood cancer that has not been fully explored to date. This pilot study will focus on twins with central nervous system (CNS) tumors who are identified through the Children's Oncology Group's Project: EveryChild (PEC) registry or volunteer.

Research Team

Jenny Poynter, PhD

Principal Investigator

University of Minnesota

Eligibility Criteria

Inclusion Criteria

A family can participate in the program if the twin affected by a central nervous system tumor has passed away but provided an APEC14B1 blood sample.

You are a patient newly diagnosed with a central nervous system tumor or have recurrent disease and enrolled in the APEC14B1 trial.

You or your legal guardian must agree to the terms of participation, and those aged 8-17 will provide assent.

Treatment Details

Participant Groups

Group I: Ancillary-Correlative Experimental Treatment 2 Interventions

Twins with CNS tumors, identified through the Children's Oncology Group's Project:EveryChild (PEC) registry, will have both blood and saliva samples collected at the time of study enrollment.

Who Is Running the Clinical Trial?

Children's Oncology Group

Lead Sponsor

Trials

467

Recruited

241,000+

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+